Research Insights Episodes

In this episode of RealTalk MS, we're talking about what you should be talking about with your neurologist or MS Specialist. Shared decision-making is a key component of patient-centered health care. It's a process in which clinicians and patients work together to make evidence-based decisions on tests, treatments, and care plans that balance risks and expected outcomes with patient preferences and values. But is shared decision-making actually occurring? Or are people living with MS still bein...

RealTalk MS is now 6 years old! We've covered a lot of ground in more than 300 episodes over the past 6 years. And I'm marking our 6-year anniversary by highlighting the most impactful conversations we've had in each of the past 6 years. We have a lot to talk about! Are you ready for RealTalk MS??! SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/317 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podc...

Just a couple of weeks ago, the FDA approved the first biosimilar medication for treating MS. As generics and now, biosimilars, become more available, it seems like the right time for us to get clear on the similarities and differences between generics, biosimilars, and the name-brand drugs that they mimic. Dr. Jiwon Oh joins me to explain everything you need to know to be an informed medical consumer when it comes to generic and biosimilar disease-modifying therapies. Dr. Oh is a neurologist, ...

Fire, flood, record-setting heat, tropical storm, earthquake -- we've seen it all in the past several weeks! Natural disasters can present a whole series of unique challenges for people affected by MS. Last year, I had an opportunity to talk about disaster preparedness for people affected by MS with Mary Casey-Lockyer, the Senior Medical Advisor to Disaster Operations at the American Red Cross. As extreme weather events become a more frequent and regular occurrence in our everyday weather patte...

Dr. Stephen Hauser's research as a physician-scientist has revolutionized our understanding of the genetics, immunology, and treatment of MS. It was Dr. Hauser's research that led to the development of a b-cell therapy for MS, which has been shown to be highly effective in treating all forms of MS and the only treatment approved for treating progressive MS. Dr. Hauser joins me this week, to discuss some of the pivotal moments in his remarkable career. Dr. Hauser's memoir, The Face Laughs While...

This special episode of RealTalk MS is sponsored by Sanofi. In this special episode of RealTalk MS, Dr. Aaron Boster walks us through everything you need to know about clinical trials. If you've ever wondered what the difference is between a Phase 1 clinical trial, a Phase 2 clinical trial, or a Phase 3 clinical trial, you're about to find out. If you're curious about how a clinical trial participant's privacy is protected, how safety is ensured, and how you can learn about clinical trials tha...

2023 marks 30 years since the very first MS disease-modifying therapy received FDA approval. To say that changed everything would be an understatement. Two of the top MS experts in the world have published a reflection, looking back at how MS research and treatment has progressed over the past 30 years and looking ahead at the challenges that remain in solving the riddle of MS. Joining me this week are the authors of that reflection, Dr. Fred Lublin and Dr. Stephen Krieger. Dr. Lublin particip...

Welcome to the 300th episode of RealTalk MS! Yikes! In last week's episode of the podcast, Dr. Bruce Bebo walked us through the latest research on the prevalence of MS in the United States, and the data serves as a clear reminder that anyone can get MS. However, not everyone with MS receives the same quality of care. My guest today is clinician-researcher Dr. Lilyana Amezcua, and we're discussing her work in exploring healthcare disparities among minority populations. In addition to celebratin...

Evidence shows that MS can affect members of minority communities differently. But how does that impact the total number of people who are living with MS? For multiple reasons, it's a tricky problem to solve. Yet, it's important that the numbers reflect everyone living with MS and no one is left behind. This week, the National MS Society's Executive Vice-President of Research, Dr. Bruce Bebo, is on hand to walk us through the just-published results of a study that provides a more granular estim...

This week, we're in New York, attending the Pathways To Cures Global Summit. The National MS Society is convening the world -- bringing together the best and brightest minds in MS research, the CEOs of major MS Societies, representatives from the pharmaceutical industry and people affected by MS -- to update the scientific foundation of the Pathways To Cures research roadmap and set the global MS research agenda for the next 3-5 years. Don't miss next week's episode of RealTalk MS, when you'll h...